In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...
This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...
Dr. Bijal Shah explores the recent advancements and shifts in treatment strategies for Ph+ ALL, driven by innovations in targeted therapies and evolving clinical practices ...
Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.
Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...
According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback